<html lang="en"><meta name="viewport" content="width=device-width, initial-scale=1" /><head><!-- Global site tag (gtag.js) - Google Analytics --><script async src="https://www.googletagmanager.com/gtag/js?id=G-2VYEP6CXDE"></script><script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag("js", new Date());  gtag("config", "G-2VYEP6CXDE");</script><link rel="stylesheet" href="../init.css"></head><body><section class="css-ps9sjo e1q9n20l0"><div class="css-nxgt9g e1wpftot0"><span class="css-1pipetz e1mwh2nm0"><a data-analytics="sidebar:section" href="/leaders/">Leaders</a></span><span class="css-1wi1zzr e1kwye4o0"> | <!-- -->Genetic screening</span></div><h1 class="css-1bo5zl0 eoacr0f0">Whole-genome sequencing of newborn babies presents ethical quandaries</h1><h2 class="css-4vhs4z ecgqxun0">It can bring medical benefits—but it could also reveal bad news</h2></section><img id="myImg" src="../image/20220514_LDP001_0.jpg" width="auto" height="200"><div class="css-1osicwh e15vdjh41"><p class="article__body-text article__body-text--dropcap" data-caps="initial"><span data-caps="initial">I</span><small>MAGINE FOR</small> a moment that your unborn child has a rare genetic disorder. Not something at least vaguely familiar, such as sickle-cell anaemia or cystic fibrosis, but rather a condition buried deep within the medical dictionary. Adrenoleukodys trophy, maybe. Or Ehlers-Danlos syndrome.</p><div class="article-audio-player"><figure class="article-audio-player__figure"><div><figcaption>Listen to this story.</figcaption> <span class="article-audio-player__cta">Enjoy more audio and podcasts on<!-- --> <a href="https://apps.apple.com/app/apple-store/id1239397626?pt=344884&amp;ct=article%20audio%20player&amp;mt=8" id="audio-ios-cta" rel="noreferrer" target="_blank">iOS</a> <!-- -->or<!-- --> <a href="https://play.google.com/store/apps/details?id=com.economist.lamarr&amp;referrer=utm_source%3Darticle%2520audio%2520player" id="audio-android-cta" rel="noreferrer" target="_blank">Android</a>.</span></div><audio class="react-audio-player" controls="" controlslist="nodownload" id="audio-player" preload="none" src="https://www.economist.com/media-assets/audio/009%20Leaders%20-%20Genetic%20screening-38358bf332058d644410752b37eb5d1a.mp3" title="https://www.economist.com/media-assets/audio/009%20Leaders%20-%20Genetic%20screening-38358bf332058d644410752b37eb5d1a.mp3"><p>Your browser does not support the &lt;audio&gt; element.</p></audio><div class="article-audio-player__center-tooltip"><style data-emotion="css sl0bi6">.css-sl0bi6{position:relative;display:inline-block;text-align:left;}</style><div class="css-sl0bi6 ey1yhxa8"><style data-emotion="css 11m9t22">.css-11m9t22{z-index:98;height:40px;width:40px;position:absolute;border-radius:50%;box-shadow:0 0 0 0 rgba(0, 0, 0, 1);-webkit-transform:scale(1);-moz-transform:scale(1);-ms-transform:scale(1);transform:scale(1);-webkit-animation:pulse-color 2s infinite;animation:pulse-color 2s infinite;}.css-11m9t22 circle{stroke:var(--ds-color-new-york-55);opacity:0.6;}@media (max-width: 22.4375rem){.css-11m9t22{top:calc(100% - 20px);left:calc(50% - 20px);}}@media (min-width: 22.5rem){.css-11m9t22{top:calc(100% - 20px);left:calc(50% - 20px);}}@-webkit-keyframes pulse-color{0%{-webkit-transform:scale(0.95);-moz-transform:scale(0.95);-ms-transform:scale(0.95);transform:scale(0.95);box-shadow:0 0 0 0 rgba(249, 195, 31, 0.7);}70%{-webkit-transform:scale(1);-moz-transform:scale(1);-ms-transform:scale(1);transform:scale(1);box-shadow:0 0 0 10px rgba(249, 195, 31, 0);}100%{-webkit-transform:scale(0.95);-moz-transform:scale(0.95);-ms-transform:scale(0.95);transform:scale(0.95);box-shadow:0 0 0 0 rgba(249, 195, 31, 0);}}@keyframes pulse-color{0%{-webkit-transform:scale(0.95);-moz-transform:scale(0.95);-ms-transform:scale(0.95);transform:scale(0.95);box-shadow:0 0 0 0 rgba(249, 195, 31, 0.7);}70%{-webkit-transform:scale(1);-moz-transform:scale(1);-ms-transform:scale(1);transform:scale(1);box-shadow:0 0 0 10px rgba(249, 195, 31, 0);}100%{-webkit-transform:scale(0.95);-moz-transform:scale(0.95);-ms-transform:scale(0.95);transform:scale(0.95);box-shadow:0 0 0 0 rgba(249, 195, 31, 0);}}</style><div class="css-11m9t22 ey1yhxa6"><svg aria-hidden="true" viewbox="0 0 100 100" xmlns="http://www.w3.org/2000/svg"><circle cx="50" cy="50" fill="transparent" r="18" stroke-width="12"></circle><circle cx="50" cy="50" fill="transparent" r="38" stroke-width="12"></circle></svg></div><style data-emotion="css 1uzxrld">.css-1uzxrld{z-index:99;position:absolute;}@media (max-width: 22.4375rem){.css-1uzxrld{top:100%;left:calc(50% - 130px);}}@media (min-width: 22.5rem){.css-1uzxrld{top:100%;left:calc(50% - 130px);}}</style><div class="css-1uzxrld ey1yhxa7"><style data-emotion="css 12d2uoj">.css-12d2uoj{box-sizing:border-box;background-color:white;font-family:var(--ds-type-system-sans);display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;gap:0.75rem;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;padding:1.5rem;-webkit-filter:drop-shadow(rgba(0, 0, 0, 0.15) 0 4px 16px);filter:drop-shadow(rgba(0, 0, 0, 0.15) 0 4px 16px);border-color:var(--ds-color-london-85);border:1px solid var(--ds-color-los-angeles-85);border-radius:0.5rem;width:260px;}</style><div class="css-12d2uoj ey1yhxa5"><style data-emotion="css 4c6dm7">.css-4c6dm7{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;-webkit-box-pack:justify;-webkit-justify-content:space-between;justify-content:space-between;}</style><div class="css-4c6dm7 ey1yhxa4"><style data-emotion="css t9wkhq">.css-t9wkhq{color:var(--ds-color-london-5);display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:end;-webkit-box-align:end;-ms-flex-align:end;align-items:end;font-size:var(--ds-type-scale-2);font-weight:500;line-height:var(--ds-type-leading-lower);}</style><div class="css-t9wkhq ey1yhxa3">Listen to this story</div><style data-emotion="css 1d5zrco">.css-1d5zrco{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;color:var(--ds-color-london-20);}.css-1d5zrco>button{height:24px;width:24px;}.css-1d5zrco>button .path-background{fill:var(--ds-color-london-35);}</style><div class="css-1d5zrco ey1yhxa2"><button aria-label="Close" class="ds-control-close _close" type="button"><svg viewbox="5 5 14 14" width="100%" xmlns="http://www.w3.org/2000/svg"><path class="path-background" d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"></path></svg></button></div></div><style data-emotion="css 1mts01m">.css-1mts01m{color:var(--ds-color-london-35);font-size:var(--ds-type-scale--1);line-height:var(--ds-type-leading-lower);margin-bottom:1rem;font-weight:400;}</style><div class="css-1mts01m ey1yhxa1"><span>Save time by listening to our audio articles as you multitask</span></div><style data-emotion="css 1cosuf1">.css-1cosuf1{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;-webkit-box-pack:justify;-webkit-justify-content:space-between;justify-content:space-between;}.css-1cosuf1>.ds-navigation-link>span{font-size:var(--ds-type-scale-0);line-height:var(--ds-type-leading-upper);color:var(--ds-color-london-35);border-bottom:1px solid var(--ds-color-london-35);}</style><div class="css-1cosuf1 ey1yhxa0"><button class="ds-slim-button" type="button">OK</button></div></div></div></div></div></figure></div><p class="article__body-text">Would you, when your child is born, want to know about it? If effective treatments were available, you probably would. But if not? If the outcome were fatal, would your interest in knowing about it depend on whether your newborn had five years of life to look forward to, or ten? Or 30?</p><p class="article__body-text">Today these questions are mostly hypothetical. Precisely because they are rare, such disorders are seldom noticed at birth. They manifest themselves only gradually, and often with unpredictable severity. But that may soon change. Twenty years after the first human genome was mapped, the price of whole-genome sequencing has fallen to a point where it could, in rich countries at least, be <a href="./21809246.html">offered routinely to newborns</a>. Parents will then have to decide exactly how much they want to know.</p><div class="advert incontent hidden advert--inline"><div><div class="adcontainer" id="econ-1"></div></div></div><p class="article__body-text">Early diagnosis brings with it the possibility of early treatment. Moreover, sequencing the genomes of newborns could offer a lifetime of returns. A patient’s genome may reveal which drugs will work best in his or her particular case for conditions such as <small>ADHD</small>, depression and cancer. Combined with information about someone’s way of life, it could highlight easily discounted health risks such as cancers and cardiovascular disease, leading to better preventive measures. A database of genomes, matched to living people, would be a boon for medical research. The fruits of that research, in turn, would make those genomes more useful to their owners as time goes on.</p><p class="article__body-text">Sequencing children’s genomes at birth would also create opportunities to develop treatments for rare conditions that are typically discovered too late and in small numbers. There are reckoned to be about 7,000 rare diseases in the world, affecting 400m people, and most are genetic. At the moment they are so unusual as to be unattractive targets for big pharmaceutical firms. With more and earlier diagnoses, that might change.</p><p class="article__body-text">Such a powerful new technology creates new dangers. Widespread screening for thousands of potentially harmful genes may be counterproductive: some results may worry parents unnecessarily, because some genetic variations, though occasionally indicative of disease, are not strongly so. Parents may not want to unlock all the secrets that their newborn’s genome might reveal. Some may indeed prefer not to know about conditions that cannot be treated. Adult-onset illnesses pose a different dilemma—a reasonable position is that it should be up to the children themselves, once grown, to decide whether they want to look at their genomic information. A further concern is that data will not be kept secure, and may be leaked or otherwise misused at some point in the future.</p><div class="advert incontent hidden advert--inline"><div><div class="adcontainer" id="econ-2"></div></div></div><p class="article__body-text">In Britain, where a large project to sequence the genomes of newborn babies is planned to start next year, a consultation process is already grappling with these questions. Some of the broad principles emerging may be applied to similar projects in a number of other European countries, and in America, Australia, China and Qatar. One lesson is to start conservatively. The British project is likely to begin with a small number of extremely reliable tests that will improve the way children are treated. This ensures the testing is for the benefit of the child. Tests that are not firmly diagnostic, or which involve much follow-up work, are not a priority. Control of the data should be passed on to children at adulthood. Finding the time to educate parents, so they can make good decisions, is essential.</p><p class="article__body-text">It remains to be seen whether the economics of this sort of testing make it feasible on a national scale. These days the cost has less to do with the technical expense of sequencing than with the salaries of those providing the services. But countries that can make this work will be able to start to harness the full potential of the genomic revolution. It began 20 years ago. Soon, it will become part of everyday health care. <span data-ornament="ufinish">■</span></p></div></body></html>